EV / EBITDA di Medicrea International SA è N/A
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracolumbar fixation; PASS TULIP, a top loading posterior fixation system; PASS DEGEN for thoracic and lumbar degenerative indications; PASS OCT, an occipito-cervico-thoracic fixation system; PASS MIS, a posterior anchoring system; PASS Antérieur that offers a range of specific implants enabling surgery using an anterior approach; IMPIX C, a sterile PEEK Optima cervical interbody device; IMPIX-C+, a sterile PEEK Optima cervical interbody device that is prefilled with bone substitute; and IMPIX-MANTA, a sterile PEEK Optima cervical interbody device that is preassembled on holder/ impactor and delivers with a disposable instrumentation kit. Its implants for cervical spine also include IMPIX-MANTA +, a sterile PEEK Optima cervical interbody device, which is prefilled with synthetic bone substitutes; and GRANVIA-C, a MRI compatible ceramic cervical disc. In addition, it provides implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar interbody device for posterior approach; IMPIX-TLIF, a sterile PEEK Optima lumbar interbody device for transforaminal approach with a pre-assembled PEEK control lead; IMPIX-ALIF, a sterile PEEK Optima lumbar interbody device for anterior approach; STABOLT, an anatomically-shaped anterior plate; OSMOSYS, a macroporous bone substitute; IMPIX-DLIF and IMPIX-DLIF SLIM sterile PEEK Optima lumbar interbody devices for direct or oblique lateral approach; and X-JAWS, a titanium lumbar staple to secure a lateral or an anterior cage. Its implants are designed to treat scoliosis, degenerative diseases, malformations, trauma, and tumors; and used in various traditional and surgical procedures. The company was founded in 1990 and is headquartered in Rillieux-la-Pape, France.